alexa Drug Price Control May Fail to Improve the Access for Patients and Exploitation of Research Innovation | Open Access Journals
ISSN: 1920-4159
Journal of Applied Pharmacy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Drug Price Control May Fail to Improve the Access for Patients and Exploitation of Research Innovation

Taha Nazir*

ICDTD Inc., 937 Northumberland Ave Saskatoon, Saskatchewan S7L3W8, Canada

*Corresponding Author:
Taha Nazir
Scientific Executive, Intellectual Consortium of Drug
Discovery and Technology Development Inc. 937
Northumberland Ave Saskatoon Saskatchewan S7L3W8, Canada
Tel: 92 321 222 0885
E-mail: taha@

Received date: January 13, 2016 Accepted date: January 14, 2016 Published date: January 20, 2016

Citation: Taha Nazir (2016) Drug Price Control May Fail to Improve the Access for Patients and Exploitation of Research Innovation. J App Pharm 8:e108. doi: 10.4172/1920-4159.1000e108

Copyright: © 2016 Nazir T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Applied Pharmacy


Current scientific efforts are not successful to inspire the researchers for innovation. However, the competitive environment may offer them new opportunities to discover the new health innovations. Whereas, the scientists are also potentially engaged to figure out more effective therapy plans and curative measures [1]. That may successful enhance the patient access at the cost of respective benefits of patents. In addition of that the reward of innovators and speculators has another important role in drug price control, patient’s access to drugs and research innovations. Moreover, the pharmaceutical institutions acquire certain innovative spotlights and promptly increase the prices. That gave another controversial hot topic to debate. The official authorities and public health care professional then introduce new ideas to control the drug prices and enforce new regulations. While, the innovators stated that the innovation is directly related the prices/ funds/grants and/or rewards. Whereas, the seriously ill patients feel their lives may cut down by delayed or stop of drugs supply. Thus, the on-going scientific investigation for novel techniques and new medication may help to enhance the access of patient to their therapy [2].

Additionally, the rising costs of prescription drugs has driven the public health care professionals to regulate the extent to which some form of price controls may be warranted. However, the health authorities have already reported the industry sponsored findings to improving the access of life saving drugs for the neediest patient. They have decided work to achieve the key goals of public health care. An introduction of new generic drugs is another serous effort to reduce competition and expanded the drug list for price control. Such trends may discourage the situation of particular market to be controlled by any specific group drug companies. We can then avoid the unnecessary reduced set of choices for the consultant physicians, pharmacists and patients [3].

Thus, the findings prompt the health professionals to revise the outdated policies in most current scenario of corporate pharmaceutical businesses. The local pricing authorities of individual countries are adding dozen medicines to the number of drugs under price control. But, providing new ammunition to the pharmaceutical manufacturers may not effectively work, because this strategy of putting more restrictions is not helping the patients. Moreover, certain professional organizations and trade groups reported the branded drug makers are grabbing overall marginal price benefits. However, there is no significant benefit for patient price control in various markets [4]. Thus, an overall envision is recommended for appropriate price control to offer additional relief for patients. That may potential control the drug prices to improve the access for patients and discourage the exploitation of research innovation.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 11th Annual Global Pharma Summit
    August 17-18, 2017 San Francisco, USA
  • 8th Annual Pharmaceutical Analysis Congress
    Sep 25-27, 2017 Vienna, Austria
  • 12th World Pharma Congress
    October 16-18, 2017 Budapest, Hungary

Article Usage

  • Total views: 7880
  • [From(publication date):
    April-2016 - Aug 16, 2017]
  • Breakdown by view type
  • HTML page views : 7820
  • PDF downloads :60

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version